November 30, 2021

the High Authority for Health recommends not to use Moderna’s vaccine for booster shots, pending a European decision

For the third dose of vaccine against Covid-19, the French health authorities recommended, Friday, October 15, to use exclusively the vaccine from Pfizer-BioNTech and to wait for an opinion from the European Medicines Agency for the use. of Moderna’s vaccine.

Read also: Article reserved for our subscribers French study confirms the effectiveness of vaccines on more than 22 million people

The recall campaign in France concerns people over 65, the immunocompromised and their relatives, people at risk, such as obese and diabetics, as well as caregivers. In each case, you must have been vaccinated for at least six months. In its latest opinion, which dates from October 6, the High Authority for Health (HAS) recommended for this recall the use of Pfizer’s vaccine, without definitively ruling out the use of that of Moderna, which has not yet obtained a marketing authorization (AMM) for the recall.

“The announcements from various health authorities have highlighted the unknowns that remain about the dose and the target population for the recall by Spikevax [vaccin de Moderna] and justify waiting for the European body to provide the details expected within the framework of the MA under examination ”, now writes the HAS in a press release on Friday.

“A position of caution”

At the beginning of October, the Scandinavian countries suspended vaccination with Moderna’s product for the youngest; in Iceland, for all adults. They announced that they would bring to the attention of the European Medicines Agency studies on a possible increased risk of myocarditis and pericarditis associated with the use of this vaccine. In any event, these diseases remain “Rare and self-limiting in almost all cases”, underlines the HAS.

Read also: Article reserved for our subscribers Scandinavian countries suspend use of Moderna’s vaccine for young people

“But this context, the currently moderate circulation of the virus and the work underway at the European Medicines Agency to define the target population [quelle limite d’âge] and especially the dosage [dose entière ou demi-dose] lead the HAS to return more strictly to a position of caution ”, she specifies. It therefore recommends waiting for the opinion of the European Medicines Agency before continuing the vaccination with Spikevax.

In contrast, in the United States, an expert committee this week recommended a booster dose of Moderna vaccine for certain population groups, a month after making the same decision for the Pfizer-BioNTech vaccine.

Our selection of articles on Covid-19 vaccines

The World with AFP